The Actinum series, once known as Takeda Pharmaceutical's signature mixed vitamin, is experiencing its biggest sales slump in more than seven years since its launch. According to drug distribution performance data, the performance of the Actinium series last year was 2.3 billion won, down 74% from 8.9 billion won in 2018. Between 2018 and 2021, Actinium EX Gold's sales were 4 billion, 2.9 billion, 1.5 billion, and 990 million won, and Actinium EX Gold recorded 4.9 billion, 3.7 billion, 2.1 billion, and 1.2 billion won during the same period. In the first half of 2022, the appearance of the two products was 140 million won and 80 million won, respectively, the worst in the past five years. Actinum, whose main ingredie